The efficacy of plant extract and bioactive compounds approaches in the treatment of pulmonary fibrosis: A systematic review

被引：29

作者：

Bahri, Sana ^{[1
,2
]}

Ben Ali, Ridha ^{[3
]}

Abidi, Anouar ^{[1
,2
]}

Jameleddine, Saloua ^{[1
,2
]}

机构：

[1] Univ Tunis El Manar, Lab Physiol, Fac Med Tunis, Tunis 1007, Tunisia

[2] Univ Manouba, Technol Ctr Sidi Thabet, Lab Physiopathol Food & Biomol LR 17 ES 03, Tunis, Tunisia

[3] Univ Tunis El Manar, Lab Expt Med, Fac Med Tunis, Tunis 1007, Tunisia

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2017年 / 93卷

关键词：

Pulmonary fibrosis; Plant extract; Bioactive compounds; FENUGREEK SEED EXTRACT; INDUCED LUNG FIBROSIS; OXIDATIVE STRESS; CITRUS-RETICULATA; PROTECTIVE ROLE; IN-VITRO; BLEOMYCIN; MICE; MEDICINE; ROSEMARY;

D O I：

10.1016/j.biopha.2017.06.052

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Pulmonary fibrosis (PF) is a lethal, chronic and progressive respiratory disease leading to interstitial lung damage and serious breathing problems. The pathogenic mechanism involves activation, migration, proliferation and differentiation of fibroblasts into myofibroblats inducing extracellular matrix accumulation that destroy lung parenchyma. Available antifibrotic treatment options are limited to Pirfenidone and Nintedanib that prevent deterioration without an improvement of this disease. The use of plant extracts and natural bioactive compounds for the treatment of PF has been known for more than thirty years in China. Nowadays, phytotherapy has gained a considerable attention in the treatment of PF both in vivo and in vitro using bleomycin (BLM)-induced lung inflammation, oxidative stress and pulmonary fibrosis in rats. In this review, we aimed to focus on the protective effects and the mechanisms of action of several plant extracts described by various research works for the treatment of PF. (C) 2017 Elsevier Masson SAS. All rights reserved.

引用

页码：666 / 673

页数：8

共 66 条

[11]

Dai L, 1996, Zhonghua Jie He He Hu Xi Za Zhi, V19, P26

[12] Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways [J].